The role will see Whelan spearheading the development and execution of Agile's market access strategy ahead of a number of key milestones for Twirla in 2020. READ: Agile Therapeutics wins FDA review extension of NDA for Twirla contraceptive Twirla, which is an investigational, once-weekly combined hormonal contraceptive patch containing ethinyl estradiol and levonorgestrel, has a PDUFA date of February 16, 2020, whereby the US Food and Drug Administration must review Agile's new drug application. Whelan brings to the team over 35 years of experience in various capacities in the healthcare industry, such as finance, sales, marketing, business development and managed markets. Agile also named Charles Grass as senior director, finance and Matthew Riley as product manager. The company's chief said in a statement that the biotech firm is excited for FDA approval.